

# Beyfortus® (nirsevimab) RSV monoclonal antibody schedule

**Beyfortus® (nirsevimab)** - RSV-specific monoclonal antibody is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract infection.

Eligibility	Medication	Dosage	Route of Administration	Reconstitute
<ul style="list-style-type: none"> <li>• Infants of mothers not given Abrysvo® vaccine during pregnancy.</li> <li>• Infants delivered within 2 weeks of Abrysvo® vaccine administration.</li> </ul>	Beyfortus® (nirsevimab)	Infants weighing less than 5 kg	50mg in 0.5ml IM	Yes
		Infants weighing more than 5 kg	100mg in 1ml IM	
<ul style="list-style-type: none"> <li>• <a href="#">Infants and young children with conditions associated with increased risk of severe RSV disease.</a> (prescribed by Paediatrician)</li> </ul>	Beyfortus® (nirsevimab)	Infants weighing less than 5 kg	50mg in 0.5ml IM	Yes
		Infants weighing more than 5 kg	100mg in 1ml IM	

Available for use only in maternity and paediatric services within a NT Health Hospital setting.

Midwives, Nurses and Aboriginal health practitioners in maternity services can administer nirsevimab under the Scheduled Substance Treatment Protocol (SSTP).